Product Name
C/EBP-epsilon (CEBPE), Polyclonal Antibody
Full Product Name
C/EBP-epsilon Antibody
Product Synonym Names
C/EBP epsilon; CCAAT/enhancer binding protein epsilon; CEBPE
Product Gene Name
anti-CEBPE antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q15744
Specificity
C/EBP-epsilon Antibody detects endogenous levels of total C/EBP-epsilon protein.
Purity/Purification
Purified from rabbit antiserum by affinity-chromatography using immunogen.
Form/Format
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Concentration
1 mg/ml (lot specific)
Target Modification
Unmodified/Total
Immunogen
The antiserum was produced against synthesized peptide derived from human C/EBP-epsilon.
Preparation and Storage
Stable at -20 degree C for at least 1 year.
Other Notes
Small volumes of anti-CEBPE antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Applications Tested/Suitable for anti-CEBPE antibody
Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), ELISA (EIA)
Application Notes for anti-CEBPE antibody
WB: 1:500~1:1000
IHC: 1:50~1:100
IF: 1:100~1:500
ELISA: 1:1000
Immunofluorescence (IF) of anti-CEBPE antibody
Immunofluorescence analysis of HeLa cells, using C/EBP-epsilon Antibody. The picture on the right is blocked with the synthesized peptide.
Immunohistochemistry (IHC) of anti-CEBPE antibody
Immunohistochemistry analysis of paraffin-embedded human brain tissue, using C/EBP-epsilon Antibody. The picture on the right is blocked with the synthesized peptide.
Western Blot (WB) of anti-CEBPE antibody
Western blot analysis of lysates from JurKat cells, treated with Insulin 0.01U/ml 15', using C/EBP-epsilon Antibody. The lane on the right is blocked with the synthesized peptide.
NCBI/Uniprot data below describe general gene information for CEBPE. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001796.2
[Other Products]
NCBI GenBank Nucleotide #
NM_001805.3
[Other Products]
UniProt Primary Accession #
Q15744
[Other Products]
UniProt Secondary Accession #
Q15745; Q8IYI2; Q99803[Other Products]
UniProt Related Accession #
Q15744[Other Products]
NCBI Official Full Name
CCAAT/enhancer-binding protein epsilon
NCBI Official Synonym Full Names
CCAAT/enhancer binding protein epsilon
NCBI Official Symbol
CEBPE??[Similar Products]
NCBI Official Synonym Symbols
CRP1; C/EBP-epsilon
??[Similar Products]
NCBI Protein Information
CCAAT/enhancer-binding protein epsilon
UniProt Protein Name
CCAAT/enhancer-binding protein epsilon
Protein Family
CCAAT/enhancer-binding protein
UniProt Gene Name
CEBPE??[Similar Products]
UniProt Synonym Gene Names
C/EBP epsilon??[Similar Products]
NCBI Summary for CEBPE
The protein encoded by this gene is a bZIP transcription factor which can bind as a homodimer to certain DNA regulatory regions. It can also form heterodimers with the related protein CEBP-delta. The encoded protein may be essential for terminal differentiation and functional maturation of committed granulocyte progenitor cells. Mutations in this gene have been associated with Specific Granule Deficiency, a rare congenital disorder. Multiple variants of this gene have been described, but the full-length nature of only one has been determined. [provided by RefSeq, Jul 2008]
UniProt Comments for CEBPE
Transcriptional activator (PubMed:26019275). C/EBP are DNA-binding proteins that recognize two different motifs: the CCAAT homology common to many promoters and the enhanced core homology common to many enhancers. Required for the promyelocyte-myelocyte transition in myeloid differentiation (PubMed:10359588).
Research Articles on CEBPE
1. Data show that both CEBPE and SMARCD2 loss-of-function mutations identified in patients with neutrophil-specific granule deficiency (SGD) abolish the interaction with SWI/SNF and secondary granule gene expression, thus providing a molecular basis for this disease.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
